←
ignacio catalan4,070 posts
ignacio catalan avatar

ignacio catalan

@ign76

MD, PhD. Gastroenterology and IBD. Norwegian University of Science, NTNU #ECCO National Rep #UEG Education Committee @YOGI_IBD Founder Keen on original ideas!💡

◷ Joined November 2010▧ 411 Photos and videos
United European Gastroenterology avatar
⟳ ignacio catalan retweeted
United European Gastroenterology@my_ueg·Nov 16

Want to shape the future of GI education in Europe? 🎓 UEG is looking for 5 new Education Committee members (2027 – 2030) to help drive our educational activities and influence how gastroenterologists learn. Be part of it! Apply by Nov 27 👉 bit.ly/3PbezgA

Post attachment
Frontline Gastro avatar
⟳ ignacio catalan retweeted
Frontline Gastro@FrontGastro_BMJ·Nov 16

🔥 🔥 Have a read of this fantastic new review looking at the role of Tumour necrosis factor-like cytokine 1A (TL1A) in IBD 🔥 🔥 TL1A drives intestinal inflammation and fibrosis, with several TL1A inhibitors showing promising phase 2 data and phase 3 trials underway. TL1A inhibition could expand future therapeutic options for IBD, potentially enabling more personalised treatment strategies 🤩 👏 Have a read of the full article ⬇️ bit.ly/3UsUo6U @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman @BSGtrainees @WorldGastroOrg @ulstergastro @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media #IBD #Crohns #UlcerativeColitis #Gastroenterology #GITwitter #GIresearch #Colitis #CCUK #MedTwitter #IBDLife #DigestiveHealth #IBDAwareness #PrecisionGI #TranslationalGI #Gastro #GastroX #IBDScience #GutHealth #ImmunologyMeetsGI #NextGenGastro

Post attachment
Aline Charabaty, MD, FACG, AGAF avatar
⟳ ignacio catalan retweeted
Aline Charabaty, MD, FACG, AGAF@DCharabaty·Nov 15

In your opinion/experience: What are the main barriers to enrolling pts in #IBD RCT ? 🗳️Tell us what you think👇🏽 📌 Nov 16 for a 🎥 convo with @EdwardLoftus2 sharing his 💭, 🔥upcoming RCTs to watch for- & how he approaches the RCT convo with his patients #MondayNightIBD

#IBDPoll1️⃣ 🆓CME👉🏼mnibd.short.gy/LoftusPost In your opinion/ experience, Which feature of the traditional RCT induction (drug vs PBO) + Re-randomize responders during maintenance- design mostly contributes to patient reluctance to enroll in RCT ?

Keith Siau avatar
⟳ ignacio catalan retweeted
Keith Siau@drkeithsiau·Nov 14

Management of C diff infection in patients with IBD - AGA Clinical Practice Update 2026

Post attachment
The Colitist avatar
⟳ ignacio catalan retweeted
The Colitist@colitist·Nov 13

Personalized therapies for Crohn's and ulcerative colitis may follow from method that identifies harmful gut bacteria medicalxpress.com/news/2026-…

David Fudman, MD avatar
⟳ ignacio catalan retweeted
David Fudman, MD@fudmanMD·Nov 11

🛑Before reducing upadacitinib to 30mg in UC, check for clinical and biochemical remission. These--not how long on 45mg--predict adverse outcomes ➡️Our practice: check PROs and FC at 6 weeks to guide dosing past 8wk 🥳to @sarah_rotondoMD and @rajdalalmed on this impactful work!

When is it safe to de-escalate upadacitinib from 45 mg in UC? In our newly published study, clinical and biochemical remission—not duration of induction—predicted successful dose de-escalation. Treat the patient, not the calendar. 🎯 Read more: doi.org/10.1093/crocol/otag1…

Malcolm Tan avatar
⟳ ignacio catalan retweeted
Malcolm Tan@IBDGastroDocSg·Nov 10

The paper is much more interesting than the title! There are many findings weaved into one scientific journey.

ignacio catalan avatar
ignacio catalan@ign76·Nov 10

❇️ Fantastic thread! Thanks for breaking this landmark paper so nicely @IBDGastroDocSg 🙌🏻

Why do some UC patients fail vedolizumab (VDZ)? A landmark study in Nature Medicine by Schreiber et al. unpacks the biological mechanism of VDZ resistance: revealing an alternative vascular bypass that might be targetable with common medications

Post attachment
Malcolm Tan avatar
⟳ ignacio catalan retweeted
Malcolm Tan@IBDGastroDocSg·Nov 5

58% of us reflexively chose to escalate to q4w. When the #VERDICT trial data dropped at #UEGWeek, that was my exact first reaction too: “Here is randomized proof that stepping up the dose captures endoscopic remission.” But that isn't what VERDICT proved. 🧵👇

Post attachment

42yo with distal UC on standard maintenance vedolizumab (300 mg q8w). At Week 16: - Stool frequency: normal - Rectal bleeding: none - Sigmoidoscopy: Mayo 2 Following the recent #VERDICT trial data from #UEGWeek, what is your next move? @my_ueg @MondayNightIBD #IBD #GITwitter

Patriciakaazan avatar
⟳ ignacio catalan retweeted
Patriciakaazan@KaazanPatricia·Nov 3

Kono-S in Crohn's ileocaecal resection (n=70, FMC & IBD SA), now in early access in Techniques in Coloproctology. Shorter stay and fewer ileostomies, but mostly explained by patient selection. Biologics, not technique, predicted 12-mo recurrence. Great work leading this @warren_seow doi.org/10.1007/s10151-026-0…

Dr. Antonio Caballero Mateos avatar
⟳ ignacio catalan retweeted
Dr. Antonio Caballero Mateos@Dr_ACaballero_·Nov 2

🧪 Perianal fistulas clear infliximab faster 📍 ATLANTIC: prospective PK cohort, 148 patients on standard IV infliximab 5 mg/kg (62 perianal fistulizing CD vs 86 luminal CD) 📈 +23% clearance in progressive perianal disease (TOpClass ≥2c) during induction 🎯 Week 14: only 9% of PFCD patients reached their target trough (≥10 µg/mL) vs 46% of luminal CD (≥5 µg/mL) 🩸 Median trough at week 14: 2.9 vs 4.8 µg/mL 💡 Authors' case: front-loaded induction plus early TDM in PFCD ⚠️ Single centre, PK study, different targets per phenotype. No RCT yet of intensified vs standard induction 👇 Key numbers in one image 🔗 doi.org/10.1093/ecco-jcc/jja… #MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #PerianalCrohns

Post attachment